Abstract
Primary liver cancer is the fifth most common cancer worldwide with an incidence rate two- to three-fold higher in developing countries than in the industrialized world [1]. Prognosis has improved in the last two decades, mainly because of earlier detection of the disease, at stages were potentially curative therapies can be applied, including surgical resection, liver transplantation and either chemical (ethanol, acetic acid) or physical (radiofrequency, microwaves, cryosurgery) percutaneous ablation. The survival of patients with non-ablatable hepatocellular carcinoma (HCC) is still poor. Several therapies have been proposed for patients who cannot benefit from a radical approach, but only transarterial embolization or chemoembolization (TAE or TACE) have been shown to improve survival in some randomized controlled trials including well-selected candidates [2]. Drug therapy, including systemic or intraarterial chemotherapy, has not been shown to increase survival, and different types of hormone therapy have also widely been tried without success.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemo-embolization improves survival. Hepatology 37:429–442
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Park W, Lim DH, Paik SW et al (2005) Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 61:1143–1150 2005
Murthy R, Nunez R, Szklaruk J et al (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25[Suppl l]:S41–55
Lau WY, Ho S, Leung TW et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583–592
Geschwind JF, Salem R, Carr BI et al (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194–205
Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10:S107–110
Reed GB Jr, Cox AJ Jr (1966) The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 48:597–611
Lawrence TS, Robertson JM, Anscher MS et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248
Cheng JC, Wu JK, Lee PC et al (2004) Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60:1502–1509
Furuse J, Ishii H, Nagase M et al (2005) Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 20:1512–1518
Cheng JC, Wu JK, Huang CM et al (2002) Radiationinduced liver disease after three-dimensional conformai radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54:156–162
Tarazov PG, Polysalov VN, Prozorovskij KV et al (2000) Ischémie complications of transcatheter arterial chemoem-bolization in liver malignancies. Acta Radiol 41:156–160
Huo TI, Wu JC, Lee PC et al (2004) Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 24:210–215
Grieco A, Marcoccia S, Miele L et al (2003) Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 50:207–212
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Iñarrairaegui, M., Sangro, B. (2008). Results in Hepatocellular Carcinoma. In: Bilbao, J.I., Reiser, M.F. (eds) Liver Radioembolization with 90Y Microspheres. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-35423-9_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-35423-9_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-35421-5
Online ISBN: 978-3-540-35423-9
eBook Packages: MedicineMedicine (R0)